Holen Sie sich die Stockscreener-App
3.57
0.28%
-0.01
Vorhandelsmarkt:
3.53
-0.04
-1.12%
Eledon Pharmaceuticals Inc Aktie (ELDN) Neueste Nachrichten
Eledon Pharmaceuticals Inc (ELDN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Eledon: At The Center Of The Next Medical Frontier (NASDAQ:ELDN) - Seeking Alpha
Eledon Pharmaceuticals Inc (ELDN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Eledon Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ELDN - TradingView
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
Eledon Pharmaceuticals, Inc. (ELDN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Eledon’s BESTOW Trial Completion: What Tegoprubart Could Mean for Transplant Investing - TipRanks
ELDN Initiated Coverage by Rodman & Renshaw -- Rating Set to Buy - GuruFocus
Eledon Pharmaceuticals stock initiated at Buy by Rodman & Renshaw - Investing.com Canada
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy - Sahm
Eledon Pharmaceuticals (ELDN) Edges Higher as Stock Approaches Key Resistance at $4.15Leading Diagonal - dars.gov.et
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell 3000 Value Benchmark - marketscreener.com
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell 2000 Value Benchmark - marketscreener.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Enterprise value to EBITDA forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN - TradingView
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Price to earnings forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN - TradingView
Price to earnings forward of Eledon Pharmaceuticals, Inc. – SWB:2TK - TradingView
Price to sales forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN - TradingView
Enterprise value to revenue forward of Eledon Pharmaceuticals, Inc. – SWB:2TK - TradingView
Enterprise value to EBIT forward of Eledon Pharmaceuticals, Inc. – SWB:2TK - TradingView
Natera (NTRA) Partners With Eledon To Put Prospera Into Phase 3 Kidney Trial - Sahm
Eledon Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ELDN) - TradingView
Eledon Teams Up With Natera on Phase 3 Study - Orange County Business Journal
Natera’s Prospera test selected for Eledon kidney transplant trial - Investing.com UK
ELDN Forecast — Price Target — Prediction for 2027 - TradingView
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial - BioSpace
Natera, Eledon Partner to Use Prospera in Phase 3 Kidney Transplant Trial - Moomoo
Natera’s Prospera test selected for Eledon kidney transplant trial By Investing.com - Investing.com Nigeria
Guggenheim Sticks to Its Buy Rating for Eledon Pharmaceuticals (ELDN) - The Globe and Mail
NEWSLETTER: Drug to prevent organ rejection after kidney transplant tops standard treatment in trial - Reuters
Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus - Sahm
Eledon Pharmaceuticals Amends Certificate of Incorporation – Key Changes Filed in 8-K SEC Report - Minichart
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney TransplantationSlideshow (NASDAQ:ELDN) 2026-06-22 - Seeking Alpha
Eledon Pharmaceuticals Expands Authorized Shares After Stockholder Vote - TipRanks
Leerink raises Eledon Pharmaceuticals price target on trial data - Investing.com
Eledon (NASDAQ: ELDN) holders approve share increase and board slate - Stock Titan
Eledon reports Phase 2 BESTOW kidney transplant data - grafa.com
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Raises Target Price to $8 - Moomoo
Eledon Pharmaceuticals Announces Long-Term Extension Phase 2 BESTOW Results for Tegoprubart in Kidney Transplantation - marketscreener.com
Eledon Pharmaceuticals (ELDN) Presents Promising Phase 2 BESTOW Study Data - GuruFocus
Cantor Fitzgerald reiterates Eledon Pharmaceuticals stock rating on kidney transplant data - Investing.com South Africa
Eledon Says Mid-Stage Data Shows Tegoprubart Offers Higher Kidney Function, Improved Outcomes Compared with Tacrolimus - marketscreener.com
Eledon reports kidney function benefit for tegoprubart at 18 months - Investing.com
Eledon reports kidney function benefit for tegoprubart at 18 months By Investing.com - Investing.com South Africa
Eledon Presents Long-Term Extension Phase 2 BESTOW Results - GlobeNewswire
Eledon trial shows all 12 diabetes patients achieve insulin independence By Investing.com - Investing.com Nigeria
Eledon Pharma To Present At The American Transplant Congress - RTTNews
Is Eledon Pharmaceuticals (ELDN) outperforming other medical stocks this year? - MSN
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):